These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

739 related articles for article (PubMed ID: 29035619)

  • 1. Personalized medicine with biologics for severe type 2 asthma: current status and future prospects.
    Godar M; Blanchetot C; de Haard H; Lambrecht BN; Brusselle G
    MAbs; 2018 Jan; 10(1):34-45. PubMed ID: 29035619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of asthma endotypes: implications for therapy.
    Stokes JR; Casale TB
    Ann Allergy Asthma Immunol; 2016 Aug; 117(2):121-5. PubMed ID: 27499539
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging Biologics in Severe Asthma.
    Pavord ID; Hilvering B; Shrimanker R
    Immunol Allergy Clin North Am; 2016 Aug; 36(3):609-23. PubMed ID: 27401629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent Patents for the Treatment of Asthma.
    El-Qutob D; Raducan I
    Recent Pat Inflamm Allergy Drug Discov; 2016; 10(1):13-20. PubMed ID: 27262358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging drugs for asthma.
    Walsh GM
    Expert Opin Emerg Drugs; 2008 Dec; 13(4):643-53. PubMed ID: 19046132
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular Targets for Biological Therapies of Severe Asthma.
    Pelaia C; Crimi C; Vatrella A; Tinello C; Terracciano R; Pelaia G
    Front Immunol; 2020; 11():603312. PubMed ID: 33329598
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-life studies of biologics used in asthma patients: key differences and similarities to trials.
    Heffler E; Paoletti G; Giorgis V; Puggioni F; Racca F; Del Giacco S; Bagnasco D; Caruso C; Brussino L; Rolla G; Canonica GW
    Expert Rev Clin Immunol; 2019 Sep; 15(9):951-958. PubMed ID: 31389304
    [No Abstract]   [Full Text] [Related]  

  • 8. Severe T2-high asthma in the biologics era: European experts' opinion.
    Pavord I; Bahmer T; Braido F; Cosío BG; Humbert M; Idzko M; Adamek L
    Eur Respir Rev; 2019 Jun; 28(152):. PubMed ID: 31285291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biologics in asthma--the next step toward personalized treatment.
    Darveaux J; Busse WW
    J Allergy Clin Immunol Pract; 2015; 3(2):152-60; quiz 161. PubMed ID: 25754716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selection of Biologics in Severe Asthma: A Multifaceted Algorithm.
    Dávila I; Quirce S; Olaguibel JM
    J Investig Allergol Clin Immunol; 2019; 29(4):325-328. PubMed ID: 30969172
    [No Abstract]   [Full Text] [Related]  

  • 11. Targeting the interleukin-4 and interleukin-13 pathways in severe asthma: current knowledge and future needs.
    Parulekar AD; Kao CC; Diamant Z; Hanania NA
    Curr Opin Pulm Med; 2018 Jan; 24(1):50-55. PubMed ID: 29036019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current and future targeted therapies for severe asthma: Managing treatment with biologics based on phenotypes and biomarkers.
    Santus P; Saad M; Damiani G; Patella V; Radovanovic D
    Pharmacol Res; 2019 Aug; 146():104296. PubMed ID: 31173886
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biologic and New Therapies in Asthma.
    Tabatabaian F; Ledford DK; Casale TB
    Immunol Allergy Clin North Am; 2017 May; 37(2):329-343. PubMed ID: 28366480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Asthma and poly(ADP-ribose) polymerase inhibition: a new therapeutic approach.
    Zaffini R; Gotte G; Menegazzi M
    Drug Des Devel Ther; 2018; 12():281-293. PubMed ID: 29483769
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Asthma phenotypes and the use of biologic medications in asthma and allergic disease: the next steps toward personalized care.
    Fajt ML; Wenzel SE
    J Allergy Clin Immunol; 2015 Feb; 135(2):299-310; quiz 311. PubMed ID: 25662302
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How to compare the efficacy of biologic agents in asthma.
    Viswanathan RK; Busse WW
    Ann Allergy Asthma Immunol; 2020 Aug; 125(2):137-149. PubMed ID: 32387169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Severe asthma: what is new in the new millennium.
    Ntontsi P; Samitas K; Zervas E; Gaga M
    Curr Opin Allergy Clin Immunol; 2020 Apr; 20(2):202-207. PubMed ID: 32004177
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Controversies and opportunities in severe asthma.
    Humbert M; Busse W; Hanania NA
    Curr Opin Pulm Med; 2018 Jan; 24(1):83-93. PubMed ID: 29059087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biologics in Asthma: Emerging Biologics.
    Desai B; Adrish M; Mohan A; Lugogo NL
    Immunol Allergy Clin North Am; 2024 Nov; 44(4):751-763. PubMed ID: 39389722
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Asthma characteristics and biomarkers from the Airways Disease Endotyping for Personalized Therapeutics (ADEPT) longitudinal profiling study.
    Silkoff PE; Strambu I; Laviolette M; Singh D; FitzGerald JM; Lam S; Kelsen S; Eich A; Ludwig-Sengpiel A; Hupp GC; Backer V; Porsbjerg C; Girodet PO; Berger P; Leigh R; Kline JN; Dransfield M; Calhoun W; Hussaini A; Khatri S; Chanez P; Susulic VS; Barnathan ES; Curran M; Das AM; Brodmerkel C; Baribaud F; Loza MJ
    Respir Res; 2015 Nov; 16():142. PubMed ID: 26576744
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.